Sartorius, a leading international laboratory and process equipment provider, grew dynamically yet again in 2011 and significantly expanded its profitability. Both Group divisions reported highs in sales revenue and earnings. The financial targets that the company had raised twice before year-end were fully achieved. Sartorius expects positive business development for the current financial year as well.
"Fiscal 2011 was an especially successful year for Sartorius, and not just in financial performance," commented Group CEO Dr. Joachim Kreuzburg. "Beyond our financials, we set the stage for the sustainable further development of the Sartorius Group within the next decade. In order to propel our business forward in an even more focused and flexible way, we have put a new division structure in place at the outset of 2012. For the current year, we also expect dynamic and profitable growth."
Dynamic growth of sales revenue and order intake
According to preliminary figures, Sartorius generated consolidated sales revenue of 733.1 million euros in fiscal 2011, up from 659.3 million euros a year ago. This equates to an increase of 11.2% (in constant currencies: 12.2%). The gain in order intake reached a similarly strong level: it jumped 10.0% (in constant currencies: 11.0%) to 749.5 million euros.
Both Group divisions contributed to this dynamic top-line performance. Sales revenue for the Biotechnology Division rose by 10.2% (in constant currencies: 11.5%) to 476.9 million euros; order intake, by 13.0% (in constant currencies: 14.3%) to 499.8 million euros. Again, business with single-use products for the biopharmaceutical industry drove this growth. Equipment business with biotechnological production systems and instruments also added positive momentum, especially due to the strong demand from Asia. The Mechatronics Division posted a gain of 13.0% (in constant currencies: 13.5%) in sales revenue, which rose to 256.2 million euros, with both businesses for laboratory instruments and industrial weighing and control products expanding at double-digit rates. The division's high growth was buoyed up by the reduction in its year-earlier order backlog and by the strong upswing in the first half. The Mechatronics Division's increase in order intake of 4.6% (in constant currencies: 5.0%) to 249.7 million euros was accordingly below the rate of sales growth.
Regionally, Sartorius again saw the highest growth rates in the Asia | Pacific region. There, sales revenue surged on the whole by 23.2%. In Europe as well, the company posted substantial gains, with sales up 10.7%. In North America, Sartorius increased its sales revenue overall by 6.2%, with the Biotechnology Division posting strong gains and the Mechatronics Division only slight increases (all figures currency-adjusted).
Overproportionate earnings development
Excellent development of sales revenue was accompanied by overproportionate gains in operating earnings and in the operating margin. In the reporting period, the Group's operating EBITA surged 31.2% to 112.2 million euros from 85.5 million euros a year ago. Its respective margin climbed by 2.3 percentage points from 13.0% to 15.3% and thus reached a new high.